Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
Kaiser PK; Registry of Visudyne AMD Therapy Writing Committee; Boyer DS, Garcia R, Hao Y, Hughes MS, Jabbour NM, Kaiser PK, Mieler W, Slakter JS, Samuel M, Tolentino MJ, Roth D, Sheidow T, Strong HA. Kaiser PK, et al. Among authors: strong ha. Ophthalmology. 2009 Apr;116(4):747-55, 755.e1. doi: 10.1016/j.ophtha.2008.12.057. Epub 2009 Feb 25. Ophthalmology. 2009. PMID: 19243834
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Bressler NM, et al. Among authors: strong ha. Arch Ophthalmol. 2002 Nov;120(11):1443-54. doi: 10.1001/archopht.120.11.1443. Arch Ophthalmol. 2002. PMID: 12427056 Clinical Trial.
Verteporfin in Photodynamic Therapy: report no. 5.
Bandello F, Blinder K, Bressler NM, Brown AL, Miller JW, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Slakter JS, Soubrane G, Strong HA, Stur M; VIP Report No. 5 Writing Committee. Bandello F, et al. Among authors: strong ha. Ophthalmology. 2004 Nov;111(11):2144. doi: 10.1016/j.ophtha.2004.08.002. Ophthalmology. 2004. PMID: 15522385 No abstract available.
Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, Immonen I, Lim JI, Menchini U, Naor J, Potter MJ, Reaves A, Rosenfeld PJ, Slakter JS, Soucek P, Strong HA, Wenkstern A, Su XY, Yang YC; Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Azab M, et al. Among authors: strong ha. Arch Ophthalmol. 2005 Apr;123(4):448-57. doi: 10.1001/archopht.123.4.448. Arch Ophthalmol. 2005. PMID: 15824216 Clinical Trial.
Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.
Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA. Blinder KJ, et al. Among authors: strong ha. Ophthalmology. 2003 Apr;110(4):667-73. doi: 10.1016/s0161-6420(02)01998-x. Ophthalmology. 2003. PMID: 12689884 Clinical Trial.
Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.
Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Strong HA, Stur M, Su XY, Virgili G; Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Blinder KJ, et al. Among authors: strong ha. Am J Ophthalmol. 2003 Sep;136(3):407-18. doi: 10.1016/s0002-9394(03)00223-x. Am J Ophthalmol. 2003. PMID: 12967792
Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3.
Arnold JJ, Blinder KJ, Bressler NM, Bressler SB, Burdan A, Haynes L, Lim JI, Miller JW, Potter MJ, Reaves A, Rosenfeld PJ, Sickenberg M, Slakter JS, Soubrane G, Strong HA, Stur M; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Arnold JJ, et al. Among authors: strong ha. Am J Ophthalmol. 2004 Apr;137(4):683-96. doi: 10.1016/j.ajo.2003.11.059. Am J Ophthalmol. 2004. PMID: 15059708
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, Zografos L, Piguet B, Pournaras CJ, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM. Schmidt-Erfurth U, et al. Among authors: strong ha. Arch Ophthalmol. 1999 Sep;117(9):1177-87. doi: 10.1001/archopht.117.9.1177. Arch Ophthalmol. 1999. PMID: 10496389 Clinical Trial.
Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.
Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L, Kapetanios AD, Lukas J, Olsen K, Potter M, Reaves A, Rosenfeld P, Schachat AP, Strong HA, Wenkstern A; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Barbazetto I, et al. Among authors: strong ha. Arch Ophthalmol. 2003 Sep;121(9):1253-68. doi: 10.1001/archopht.121.9.1253. Arch Ophthalmol. 2003. PMID: 12963608
A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.
Sickenberg M, Schmidt-Erfurth U, Miller JW, Pournaras CJ, Zografos L, Piguet B, Donati G, Laqua H, Barbazetto I, Gragoudas ES, Lane AM, Birngruber R, van den Bergh H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM. Sickenberg M, et al. Among authors: strong ha. Arch Ophthalmol. 2000 Mar;118(3):327-36. doi: 10.1001/archopht.118.3.327. Arch Ophthalmol. 2000. PMID: 10721954 Clinical Trial.
34 results